• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regeneron

Regeneron touts results of NIH-sponsored EYLEA injection study

March 31, 2021 By Sean Whooley

Regeneron - updated

Regeneron Pharmaceuticals (NSDQ:REGN) announced data supporting the use of its EYLEA injection in NPDR patients. Protocol W, a NIH-sponsored trial to evaluate the EYLEA (aflibercept) injection in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR), without center-involved diabetic macular edema (CI-DME), had its initial results published in JAMA Ophthalmology. At two years, the primary […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: National Institutes of Health, Regeneron

Regeneron touts one-year diabetic retinopathy data for Eylea

February 11, 2019 By Sarah Faulkner

Regeneron - updated

Regeneron Pharmaceuticals (NSDQ:REGN) touted one-year results from a Phase III trial of its Eylea aflibercept injection in people with moderately severe to severe non-proliferative diabetic retinopathy. The primary endpoint of the two-year Panorama trial is the proportion of patients who experience a two-step or greater improvement in the ‘diabetic retinopathy severity scale.’ Of the 133 people […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Regeneron

Clearside Biomedical’s combo therapy fails in Ph3 retinal vein occlusion trial

November 5, 2018 By Sarah Faulkner

Clearside Biomedical logo - updated

Clearside Biomedical (NSDQ:CLSD) said today that its lead drug, in combination with Regeneron‘s (NSDQ:REGN) Eylea, failed in a phase III retinal vein occlusion trial. The trial’s primary endpoint was the proportion of patients in the combination treatment arm, compared to the group receiving just intravitreal Eylea, that experienced improvements in best corrected visual acuity after eight weeks. […]

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Clearside Biomedical, Regeneron

FDA to review Regeneron’s Eylea for diabetic retinopathy

September 13, 2018 By Sarah Faulkner

Regeneron - updated

Regeneron Pharmaceuticals (NSDQ:REGN) said today that the FDA plans to review the supplemental biologics license application for Regeneron’s Eylea aflibercept injection for the treatment of diabetic retinopathy. The U.S. agency plans to make a decision about the blockbuster drug by May 13, 2019. Regeneron’s Eylea is dosed using a two-milligram intravitreal injection and is already approved […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Regeneron

Bayer wins second approval in China for Eylea eye drug

May 17, 2018 By Sarah Faulkner

Bayer

Bayer (ETR:BAYN) said today that its eye drug, Eyelea, was approved by the Chinese authorities to treat patients with wet age-related macular degeneration. The pharmaceutical giant’s aflibercept injection is already cleared in China to treat visual impairment due to diabetic macular edema. Age-related macular degeneration accounts for 8.7% of all blindness, according to Bayer – that’s […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Bayer AG, Regeneron

Regeneron, Sanofi strike pricing deal with Express Scripts for cholesterol drug

May 1, 2018 By Sarah Faulkner

Regeneron, Sanofi

Regeneron Pharmaceuticals (NSDQ:REGN) and its partner, Sanofi (NYSE:SNY), have agreed to lower the cost for its cholesterol drug, Praluent, for Express Scripts (NSDQ:ESRX) in exchange for an exclusive spot on the pharmacy benefit manager’s national formulary. The agreement, effective July 1, is designed to broaden patient access to the injectable medicine and lower out-of-pocket costs for eligible […]

Filed Under: Cardiovascular, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Express Scripts, Regeneron, Sanofi-Aventis

Regeneron unveils topline Ph3 diabetic retinopathy data for blockbuster eye drug

March 20, 2018 By Sarah Faulkner

Regeneron

Regeneron Pharmaceuticals‘ (NSDQ:REGN) eye drug Eylea brought in nearly $6 billion in sales last year. In an attempt to keep the injectable drug in a league of its own, the biotech plans to apply for a new indication with the FDA this year. The company today announced results from a Phase III trial evaluating Eylea in […]

Filed Under: Clinical Trials, Diabetes, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Regeneron

Eylea wins approval in China for diabetic macular edema

February 13, 2018 By Sarah Faulkner

Bayer

Bayer (ETR:BAYN) said today that the Chinese State Food and Drug Administration has approved Eylea to treat patients who have visual impairment due to diabetic macular edema. It’s the first indication for Eylea to be approved by the Chinese regulatory body. The injectable eye drug is sold by Regeneron (NSDQ:REGN) in the U.S. and has been approved […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Bayer AG, Regeneron

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

January 4, 2018 By Sarah Faulkner

Momenta Pharmaceuticals (NSDQ:MNTA) and Mylan (NSDQ:MYL) announced yesterday that they plan to launch a pivotal trial in the first half of 2018 for a proposed biosimilar to Regeneron‘s (NSDQ:REGN) blockbuster drug, Eylea. Eylea, a VEGF-inhibitor designed to treat wet age-related macular degeneration and diabetic macular edema, has little competition on today’s market. The drug brought in […]

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: momentapharmaceuticals, Mylan, Regeneron

How this biotech plans to go up against big pharma with its eye disease products

December 29, 2017 By Sarah Faulkner

Ocugen

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Massachusetts Eye & Ear Infirmary, ocugen, Pfizer Inc., Regeneron, Roche, Shire

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS